← Back to headlines
Haisco Licenses Pre-Clinical Drug to US Venture for $1.5 Billion
Chinese biotech firm Haisco Pharmaceutical has licensed a pre-clinical stage drug candidate to a US-based venture capital firm in a deal valued at $1.5 billion.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
